Mohammed A Azab

Dr. Mohammed A Azab


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
YMYusuf Mehkri
Yusuf Mehkri
SWSamuel Woodford
Samuel Woodford
Kevin PierreKevin Pierre
Kevin Pierre
ADAbeer Dagra
Abeer Dagra
JHJairo Hernandez
Jairo Hernandez
Brandon Lucke-WoldBrandon Lucke-Wold
Brandon Lucke-Wold
Chemotherapy as an adjuvant therapy that has largely failed to significantly improve outcomes for aggressive brain tumors; some reasons include a weak blood brain barrier penetration and tumor heterogeneity. Recently, there has been interest in designing effective ways to deliver chemotherapy to the tumor. In this review, we discuss the mechanisms of focused chemotherapies that are currently under investigation. Nanoparticle delivery demonstrates both a superior permeability and retention. However, thus far, it has not demonstrated a therapeutic efficacy for brain tumors. Convection-enhanced delivery is an invasive, yet versatile method, which appears to have the greatest potential. Other vehicles, such as angiopep-2 decorated gold nanoparticles, polyamidoamine dendrimers, and lipid nanostructures have demonstrated efficacy through sustained release of focused chemotherapy and have either improved cell death or survival in humans or animal models. Finally, focused ultrasound is a safe and effective way to disrupt the blood brain barrier and augment other delivery methods. Clinical trials are currently underway to study the safety and efficacy of these methods in combination with standard of care.

1 March 2019 in World Neurosurgery
Verified
Journal Article
Closed access
AAAbdullah M. Abunimer
Abdullah M. Abunimer
HAHussam Abou-Al-Shaar
Hussam Abou-Al-Shaar
MAMohammed A Azab
Mohammed A Azab
MKMichael Karsy
Michael Karsy
JGJian Guan
Jian Guan
WCWilliam T. Couldwell
William T. Couldwell

1 November 2018 in World Neurosurgery
Verified
Journal Article
Closed access
HAHussam Abou-Al-Shaar
Hussam Abou-Al-Shaar
MAMohammed A Azab
Mohammed A Azab
MKMichael Karsy
Michael Karsy
JGJian Guan
Jian Guan
WCWilliam T. Couldwell
William T. Couldwell
RJRandy L. Jensen
Randy L. Jensen

25 September 2023 in Journal of Molecular Pathology
Verified
Journal Article
Open access
PDF file
MAMohammed A Azab
Mohammed A Azab
Glioblastoma (GBM) is considered the most aggressive primary brain tumor. Recurrence after treatment is a significant problem with a failed response to optimal therapies. The recurrence of GBM is linked to different cellular and molecular pathways. Not only genetics are involved in gliomagenesis, but also epigenetics. Histone modulation through acetylation, phosphorylation, ubiquitination, and methylation can regulate gene expression and may play a role in the pathogenesis of GBM. Preclinical and clinical studies currently target epigenetic enzymes in gliomas, including a new generation of histone deacetylase (HDAC) inhibitors. Herein, I tried to highlight current research in glioma epigenetics, focusing on the culprit of histone modifications and the use of HDAC target therapies as a possible treatment line for glioblastoma.

13 January 2023 in Encyclopedia
Verified
Journal Article
Open access
PDF file
Mohammad Reza Hosseini SiyanakiMohammad Reza Hosseini Siyanaki
Mohammad Reza Hosseini Siyanaki
MAMohammed A Azab
Mohammed A Azab
Brandon Lucke-WoldBrandon Lucke-Wold
Brandon Lucke-Wold
Traumatic optic neuropathy is one of the causes of visual loss caused by blunt or penetrating head trauma and is classified as both direct and indirect. Clinical history and examination findings usually allow for the diagnosis of traumatic optic neuropathy. There is still controversy surrounding the management of traumatic optic neuropathy; some physicians advocate observation alone, while others recommend steroid therapy, surgery, or both. In this entry, we tried to highlight traumatic optic neuropathy’s main pathophysiologic mechanisms with the most available updated treatment. Recent research suggests future therapies that may be helpful in traumatic optic neuropathy cases.

1 December 2021 in Interdisciplinary Neurosurgery
Verified
Journal Article
Open access
MAMohammed A Azab
Mohammed A Azab
AAAhmed Y. Azzam
Ahmed Y. Azzam
ASAhmed E. Salem
Ahmed E. Salem
ARAhmed Reda
Ahmed Reda
SHSherif F. Hassanein
Sherif F. Hassanein
IGIslam S. Gadelmoula
Islam S. Gadelmoula
Background: COVID-19 infection has spread so fast in both low- and high-income countries. In December 2019, an outbreak of a respiratory disease occurred in China, and later, it involved different countries. Acute neurological insults are more likely to occur in severely infected patients. Methods: We tried to evaluate patients with selective criteria including, the age of participants 18 and older with a confirmed diagnosis of SARS-CoV-2, and developed neurological complications post COVID-19 infection. An overall data of 1500 patients were collected from neurological and primary health care departments. About 970 of them had neurological problems. Patients-related data were gathered and assembled from the patients' records at participating hospitals from the Ministry of Health and university hospitals. Results: We presented the results according to several variables including, regional distribution, reasons of presentation, neurological complications, follow-ups, and survival outcome. Conclusions: To our knowledge, we conducted the first retrospective analysis for neurological problems related to COVID-19 infection in Egypt. COVID-19 patients present with a variety of central and peripheral neurological symptoms, the pathogenic mechanisms of which have not been explained. Robust investigations of the neurological presentations of COVID-19 infection should be recruited for better understanding of the possible association. Moreover, further explaining the pathophysiologic mechanisms will help in designing proper treatment plans.